Attapon Cheepsattayakorn^1,2*, Ruangrong Cheepsattayakorn³ and Porntep Siriwanarangsun¹

¹Faculty of Medicine, Western University, Pathumtani Province, Thailand

*Corresponding Author: Attapon Cheepsattayakorn, 10^th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand.

Received: December 22, 2022; Published: January 01, 2023

Cellular or antibody responses is measured in the most studies of immunity to SARS-CoV-2 (COVID-19) [1]. Nevertheless, if ever SARS-CoV-2 (COVID-19) present in the plasma, the infectious virus is rarely infects the nasal and conjunctival mucosal surfaces [1]. In COVID-19-infected-unvaccinated and unvaccinated-COVID-19-uninfected individuals, the levels of nasal and salivary anti-spike antibody correlated significantly with plasma antibody [1,2]. The reported mean correlations for titers in plasma and saliva for IgG and IgA were moderate (p = 0.55; 95% CI: 0.38-9.73) and weak (p = 0.28; 95% CI: 0.12-0.44), respectively [2]. A previous systematic review demonstrated that previous-COVID-19-infected-vaccinated individuals demonstrated boosting anti-spike antibody levels in the nose or saliva less than in plasma [1].

References

1. Cohen JI., et al. “Comparison of levels of nasal, salivary, and plasma antibody to SARS-CoV-2 during natural infection and after vaccination”. Clinical Infectious Diseases (2022).
2. Guerra ENS., et al. “Saliva is suitable for SARS-CoV-2 antibodies detection after vaccination: a rapid systematic review”. Frontiers in Immunology (2022).

Citation

Citation: Attapon Cheepsattayakorn. “Level Differences of Plasma, Nasal, and Salivary Antibody to SARS-CoV-2 (COVID-19) During Natural Infection and After COVID-19 Vaccination". Acta Scientific Microbiology 6.2 (2023): 01.

Copyright

Copyright: © 2022 Attapon Cheepsattayakorn. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.